Related Experiment Video
Updated: Jul 18, 2026
09:38
Generalized Psychophysiological Interaction (PPI) Analysis of Memory Related Connectivity in Individuals at Genetic Risk for Alzheimer's Disease
Published on: November 14, 2017
Primary prevention trials in Alzheimer disease
Robert C Green1, Steven T DeKosky
1Department of Neurology, Boston University School of Medicine, Boston, MA 02118, USA. rcgreen@bu.edu
Neurology
|November 15, 2006
Summary
Designing primary prevention trials for Alzheimer disease (AD) presents significant challenges. Secondary prevention trials offer a more feasible initial approach for evaluating new AD treatments.
Area of Science:
- Neurology
- Clinical Trials
- Alzheimer Disease Research
Background:
- Emerging Alzheimer disease (AD) treatments aim for disease modification, not just symptom management.
- Evaluating these novel therapies necessitates robust clinical trial designs, including primary and secondary prevention studies.
Purpose of the Study:
- To outline the methodological challenges inherent in designing primary prevention trials for Alzheimer disease.
- To illustrate these challenges using examples from the Alzheimer Disease Anti-Inflammatory Prevention Trial (ADAPT) and Ginkgo in Evaluation of Memory (GEM) studies.
Main Methods:
- Review of design considerations for primary prevention trials in Alzheimer disease.
- Case study analysis of the ADAPT and GEM studies to highlight practical challenges.
Main Results:
- Primary prevention trials for AD face numerous complex design hurdles.
- These challenges underscore the difficulties in establishing effective preventative strategies.
Conclusions:
- Designing primary prevention trials for Alzheimer disease is methodologically demanding.
- Secondary prevention trials represent a more practical initial step towards achieving primary prevention goals for AD.
Related Concept Videos
01:22Alzheimer's Disease: Treatment
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
01:26Alzheimer's Disease: Overview
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ and tau...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ and tau...
01:29Alzheimer Disease l: Introduction
Alzheimer disease is a chronic, progressive, and irreversible neurodegenerative disorder and the most common cause of dementia in older adults. It leads to gradual neuronal loss, causing cognitive decline, behavioral changes, and loss of functional independence.Risk Factors and EtiologyThe disease is multifactorial. Age is the strongest risk factor, with prevalence doubling every 5 years after age 65. Genetic factors include mutations in genes such as APP, PSEN1, and PSEN2, which are associated...
01:23Alzheimer Disease ll: Pathophysiology
Alzheimer disease involves structural changes in the brain that begin long before symptoms appear. The most distinctive features are extracellular neuritic plaques and intracellular neurofibrillary tangles.Neuritic plaques form in the cerebral cortex and around blood vessels. These plaques contain a dense core of beta-amyloid (Aβ)—a toxic protein fragment that clumps outside neurons. The core is surrounded by damaged neuronal extensions, as well as reactive astrocytes and microglia. Abnormal...
01:16Clinical Trials
Clinical trials are prospective experimental studies conducted on humans to determine the safety and efficacy of treatments, drugs, diet methods, and medical devices. Using statistics in clinical trials enables researchers to derive reasonable and accurate conclusions from the collected data, allowing them to make wise decisions in uncertain situations. In medical research, statistical methods are crucial for preventing errors and bias.
There are four phases in a clinical trial. A phase one...
There are four phases in a clinical trial. A phase one...
01:11Clinical Trials: Overview
Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...